

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC.,)
INNOPHARMA LICENSING LLC,)
INNOPHARMA INC., INNOPHARMA LLC,) Case IPR2015-00902
MYLAN PHARMACEUTICALS INC.) (Patent 8,669,290 B2)
and MYLAN INC.)
 Petitioner,) Case IPR2015-00902
 v.) (Patent 8,129,431 B2)
SENJU PHARMACEUTICAL CO., LTD.,)
BAUSCH & LOMB, INC., and)
BAUSCH & LOMB PHARMA HOLDINGS CORP.)
 Patent Owner.)
-----)

CONFIDENTIAL SUBJECT TO THE PROTECTIVE ORDER

VIDEOTAPED DEPOSITION OF JOHN C. JAROSZ

Washington, DC 20001

Thursday, March 3, 2016

Reported by: Denise D. Vickery, CRR/RMR

<p style="text-align: right;">Page 2</p> <p>1 Thursday, March 3, 2016 2 9:04 a.m. 3 4 5 VIDEOTAPED DEPOSITION OF JOHN C. JAROSZ, held at the 6 offices of: 7 8 FINNEGAN HENDERSON FARABOW 9 GARRETT & DUNNER, LLP 10 901 New York Avenue NW 11 Washington, DC 20001 12 13 Pursuant to notice, before Denise D. Vickery, 14 Registered Merit Reporter, Certified Realtime 15 Reporter, and Notary Public in and for the District 16 of Columbia. 17 18 19 20 21 22</p>	<p style="text-align: right;">Page 4</p> <p>1 A P P E A R A N C E S (continued) 2 3 For the Lupin Petitioner: 4 GROWELL & MORING 5 1001 Pennsylvania Avenue NW 6 Washington, DC 20004-2595 7 202.624.2897 8 BY: SHANNON LENTZ, ESQ. 9 slentz@crowell.com 10 11 12 13 Also Present: 14 15 T. J. O'Toole, Videographer 16 17 18 19 20 21 22</p>
<p style="text-align: right;">Page 3</p> <p>1 A P P E A R A N C E S 2 3 For the Petitioners: 4 ALSTON & BIRD LLP 5 333 South Hope Street, Sixteenth Floor 6 Los Angeles, CA 90071 7 213.576.1000 8 BY: HIDETADA JAMES ABE, ESQ. 9 james.abe@alston.com 10 11 12 13 For the Patent Owner: 14 FINNEGAN HENDERSON FARABOW GARRETT & DUNNER, LLP 15 901 New York Avenue NW 16 Washington, DC 20001 17 202.408.4000 18 BY: JESSICA M. LEBEIS, ESQ. 19 jessica.lebeis@finnegan.com 20 21 22</p>	<p style="text-align: right;">Page 5</p> <p>1 I N D E X 2 3 EXAMINATION OF JOHN C. JAROSZ PAGE 4 5 BY MR. ABE 12 6 7 -oOo- 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22</p>

Page 6			Page 8		
1	E X H I B I T S		1	E X H I B I T S (continued)	
2			2	(Previously marked)	
3	EXHIBIT	DESCRIPTION PAGE	3	EXHIBIT	DESCRIPTION PAGE
4	InnoPharma EX1056	Valeant Pharmaceuticals 168	4	Senju Exhibit 2130	Declaration of 15
5		International Management	5		John C. Jarosz
6		Discusses Q2 2013	6		Page 1 – 123
7		Results – Earnings	7		
8		Call Transcript	8		
9			9	Senju Exhibit 2153	CDER Application Number: 196
10	E X H I B I T S		10		2031680rig1s000
11	(Previously marked)		11		Summary Review Page 1 – 22
12			12		
13	EXHIBIT	DESCRIPTION PAGE	13	Senju Exhibit 2191	ASCRS EyeWorld Pharmaceutical 204
14	InnoPharma EX1054	Assessing Commercial Success 51	14		Focus: Getting the scoop
15		at the U.S. Patent Trial	15		on NSAIDs for cataract surgery
16		and Appeal Board John Jarosz	16		
17		and Robert L. Vigil	17	Senju Exhibit 2220	[REDACTED] 107
18			18		[REDACTED]
19	InnoPharma Exhibit 1066	Deposition of WITHDRAWN	19		[REDACTED]
20		John Jarosz on	20		
21		February 17, 2016	21		
22	///		22	///	
Page 7			Page 9		
1	E X H I B I T S (continued)		1	E X H I B I T S (continued)	
2	(Previously marked)		2	(Previously marked)	
3			3		
4	EXHIBIT	DESCRIPTION PAGE	4	EXHIBIT	DESCRIPTION PAGE
5	Senju Exhibit 2002	United States Patent 49	5	Senju Exhibit 2226	[REDACTED] 97
6		8, 129, 431 Sawa et al.	6		[REDACTED]
7		Page 1 – 8	7		[REDACTED]
8			8		[REDACTED]
9	Senju Exhibit 2013	Prolensa Label Page 1 – 6 138	9		
10			10	Senju Exhibit 2229	Bausch & Lomb Submits New 159
11	Senju Exhibit 2024	Stipulated Consent Judgment 179	11		Drug Application for
12		and Injunction Bausch & Lomb	12		Once-Daily Prolensa
13		v. Apotex Page 1 – 4	13		to Treat Ocular
14			14		Inflammation and Pain
15	Senju Exhibit 2122	Stipulated Consent Judgment 179	15		Following Cataract Surgery
16		and Injunction Bausch &	16		Page 1 – 2
17		Lomb v. Metrics Page 1 – 4	17		
18			18	Senju Exhibit 2232	The Economics of Commercial 114
19	Senju Exhibit 2123	Stipulated Consent Judgment 179	19		Success in Pharmaceutical
20		and Injunction Bausch &	20		Patent Litigation, Guha et al.
21		Lomb v. Paddock	21		Page 1 – 5
22		Page 1 – 5	22	///	

	Page 10		Page 12
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 10 E X H I B I T S (continued) (Previously marked) EXHIBIT DESCRIPTION PAGE Senju Exhibit 2235 Valeant Pharmaceuticals 152 International. Solid results; Increased Guidance. CIBC Page 1 - 10 -oOo-		1 Bird for the InnoPharma Petitioner and Mylan 2 Petitioner. 3 MS. LENTZ: Shannon Lentz of 4 Crowell & Moring here for Petitioner Lupin. 5 MS. LEBEIS: Jessica Lebeis of 6 Finnegan on behalf of the Patent Owners Senju and 7 Bausch & Lomb. 8 THE VIDEOGRAPHER: Thank you. 9 Would the court reporter please 10 swear in the witness. 11 - - - 12 JOHN C. JAROSZ 13 called for examination, and, after having been duly 14 sworn, was examined and testified as follows: 15 EXAMINATION 16 BY MR. ABE: 17 Q. Good morning, Mr. Jarosz. 18 A. Good morning. 19 Q. Can you state your name for the record? 20 A. John C. Jarosz. 21 Q. You've been deposed many times before; 22 right?
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 11 P R O C E E D I N G S - - - THE VIDEOGRAPHER: On the record with disk No. 1 of the video deposition of John Jarosz taken by the Petitioner in the matter of InnoPharma Licensing, Incorporated, et al. versus Senju Pharmaceuticals Company Limited, et al., being heard before the Patent Trial and Appeal Board of the United States Patent and Trademark Office, Case No. IPR2015-00902. This deposition is being held at the Finnegan law offices located at 901 New York Avenue Northwest in Washington, DC on March 3, 2016 at approximately 9:04 a.m. My name is T.J. O'Toole. I am the certified legal video specialist. The court reporter is Denise Vickery. We are both here representing Gregory Edwards, LLC. Will counsel please introduce themselves and indicate which parties they represent. MR. ABE: James Abe of Alston &		Page 13 1 A. Yes, only in different matters. 2 Q. Of course. 3 A. Many different matters. 4 Q. Yes. I just wanted to go over the 5 ground rules. 6 A. (Nods head). 7 Q. I represent the InnoPharma Petitioners 8 and I'll be asking questions today, and I'll ask 9 that you answer my questions. Your counsel might 10 object, but unless she instructs you not to answer, 11 I expect you to answer. 12 Is that okay? 13 A. Yes. 14 Q. If you don't understand a question I'm 15 asking, just let me know. If you need a break, just 16 let me know, but I ask that you answer any pending 17 question before you do that. 18 Is that okay? 19 A. Yes. 20 Q. Okay. Is there any reason why you 21 can't testify truthfully today? 22 A. No.

Page 14	Page 16
<p>1 MR. ABE: Okay. Counsel, will you 2 stipulate that the witness is here for 3 cross-examination for both IPR2015-00902 and 903? 4 MS. LEBEIS: Yes. 5 MR. ABE: Okay. And will counsel 6 also stipulate that my questions will be directed to 7 both IPR proceedings unless I specify otherwise? 8 MS. LEBEIS: Yes. 9 BY MR. ABE: 10 Q. Okay. Mr. Jarosz, have you ever been 11 deposed in the context of an inter partes review 12 proceeding? 13 A. Yes. 14 Q. How many times? 15 A. I'd have to look at my CV, but my best 16 memory right now is that it's been three times. I 17 might be wrong, however. 18 Q. And your CV, I believe, is attached as 19 one of the exhibits or it is attached to your 20 declaration; is that right? 21 A. I have attached the version of my CV 22 that was current as of the time I submitted my</p>	<p>1 Well, I'm not exactly sure. I believe 2 so, but I see a few redactions in this, and I am not 3 sure that what I submitted had redactions. So I'm 4 not positive -- 5 Q. Yeah, this is -- 6 A. -- that this is what I submitted. 7 Q. Right. There's another version that is 8 the board's only -- eyes only, but for today's 9 proceeding I'd like to use the board version that's 10 redacted. 11 Is that okay? 12 A. I think so. Although I'm a little bit 13 nervous since it doesn't look like exactly the 14 document that I submitted. 15 Q. That's fair. 16 I'll just represent to you that this is 17 what was filed by the patent owners in the case as 18 protective order material with the redactions as you 19 noted. 20 Is that okay? 21 A. Yes. 22 Q. Okay. So why don't you turn to the CV,</p>
<p>Page 15</p> <p>1 report or declaration in this matter. 2 Q. Do you recall when those three -- let 3 me restate it. 4 Were those three depositions for the 5 inter partes review -- would that have happened 6 after you submitted your declaration in this case? 7 A. No, I don't think any have been 8 since -- 9 Q. Okay. 10 A. -- the declaration in this matter. 11 Though I might be wrong. I think I'm correct. 12 Q. Were any of those IPR proceedings in 13 relation to patents that covered pharmaceutical 14 subject matter? 15 A. I'd have to go back and check. I don't 16 recall sitting here right now. 17 Q. Okay. Maybe if I hand you your 18 declaration, that might help. So I'm -- so I'm 19 handing you what's been marked Senju Exhibit 2130 in 20 the 902 IPR. 21 Mr. Jarosz, is this your declaration? 22 A. (Reviewing document).</p>	<p>Page 17</p> <p>1 which is attached to your declaration as Appendix 1. 2 On page 69, it lists your patent cases. 3 Do you see that? 4 A. Well, it's the start of the list of my 5 patent cases. 6 Q. And the second case listed there, 7 that's an IPR proceeding? 8 A. If that's a question, the answer is 9 yes. 10 Q. Yeah. And you represented the Polaris 11 Industries, Inc. company? 12 A. Yes. 13 Q. Is that right? 14 A. Our firm did, yes. 15 Q. Okay. And that case didn't involve a 16 pharmaceutical product, did it? 17 A. No. 18 Q. And you represented petitioner -- 19 sorry. 20 You were representing the patent owner 21 in that case; is that right? 22 MS. LEBEIS: Objection to the form</p>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.